Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease

Inclusion Criteria

• •1. Allogeneic hematopoietic stem cell transplantation for any malignant or non-malignant disease.
• •2. Age 0-17.99 years at the time of transplantation.
• •3. Bone marrow, peripheral blood stem cell and umbilical cord blood (including single or double cord blood) as the graft source.
• •4. Any conditioning regimen with any chemotherapy / radiation therapy combination. Haploidentical donor transplants with post-transplant cyclophosphamide are also allowed.
• •5. Use of serotherapy is permitted.
• •6. Any graft-versus-host disease prophylaxis is permitted, including post-HSCT cyclophosphamide.
• •7. If participant weighs between 0-20 kg, participant must be able to provide 15 ml of whole blood at each time point.
• •8. If participant weighs over 20 kg, participant must be able to provide 1ml/kg of whole blood, up to a maximum of 23 mL for the pre-conditioning sample and 32 mL for samples at day +100, 6-months, 12-months, +/- the cGVHD sample.
• •9. Written informed consent from parents.
• •10. Assent from study participant when appropriate.
• •11. Participation on other clinical trials is acceptable.